Table 1

Proportion of patients (%) with a positive or negative anti-CCP test at baseline in relation to continuing or prescribed treatment during the study

DMARD	0 Months			3 Months			6 Months			12 Months			24 Months			36 Months
DMARD	CCP+	p	CCP−	CCP+	p	CCP−	CCP+	p	CCP−	CCP+	p	CCP−	CCP+	p	CCP−	CCP+	p	CCP−
MTX, methotrexate; SSZ, sulfasalazine; antimalarial drugs, chloroquine phosphate or hydroxychloroquine; gold, sodium aurothiomalate or auranofin; other, for example, azathioprine, cyclosporin A, alkylating agents, and penicillamine.
NS, not significant; p<0.05; p<0.01; **p<0.001.
None	48.1	*	64.2	17.3	*******	42.4	18.6	**	36.5	14.7	*******	36.5	24.4	*******	48.2	25.6	**	47.1
MTX	28.2	**	11.8	46.2	*******	24.7	48.7	**	28.2	40.4	NS	28.2	30.1	NS	27.1	34	*	21.2
SSZ	19.9	NS	16.5	23.1	NS	16.5	19.2	NS	12.9	19.9	NS	11.8	16.7	NS	9.4	11.5	NS	11.8
Antimalarial drugs	10.6	NS	3.5	5.1	NS	7.1	3.8	*	11.8	7.1	NS	11.8	5.1	NS	8.2	1.6	*	9.4
Gold	1.3	NS	2.4	4.5	NS	4.7	5.8	NS	4.7	4.5	NS	3.5	3.2	NS	1.2	5.1	NS	1.2
Other	1.3	NS	3.5	2.6	NS	3.5	0.6	NS	2.4	2.6	NS	3.5	4.5	NS	3.5	4.5	NS	3.5
Combination	0.6	NS	0	1.3	NS	1.2	3.2	NS	3.5	10.9	NS	4.7	15.4	**	2.4	10.9	NS	4.7
Etanercept/infliximab	0	NS	0	0	NS	0	0	NS	0	0	NS	0	0.6	NS	0	6.4	NS	1.2